DrugPatentWatch Database Preview

ZERVIATE Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Zerviate patents expire, and when can generic versions of Zerviate launch?

Zerviate is a drug marketed by Eyevance and is included in one NDA. There are four patents protecting this drug.

This drug has fifteen patent family members in five countries.

The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-nine suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Zerviate

A generic version of ZERVIATE was approved as cetirizine hydrochloride by TEVA PHARMS on May 27^th, 2008.

Summary for ZERVIATE

International Patents:	15
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	75
Patent Applications:	4,115
Formulation / Manufacturing:	see details
DailyMed Link:	ZERVIATE at DailyMed

Pharmacology for ZERVIATE

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

Synonyms for ZERVIATE

(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid

(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid

(2-{4-[(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid (2HCl)

[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid

[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1-piperazinyl] ethoxy] acetic acid

[2-[4-[(4-chlorophenyl)phenylmethyl] 1-piperazinyl]-ethoxy] acetic acid

[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-ethoxy]acetic acid

[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid

110271-EP2284166A1

110271-EP2298415A1

2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid

2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid

2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazino}ethoxy)acetic acid

2-(2-{4-[(4-chlorophenyl)phenylmethyl]piperazinyl}ethoxy)acetic acid

2-[2-[4-[(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid

2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid

2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid

24161-EP2272832A1

24161-EP2281815A1

24161-EP2295409A1

24161-EP2301933A1

24161-EP2305640A2

24161-EP2311827A1

24161-EP2314590A1

81C510

83881-51-0

83881-52-1 (di-hydrochloride)

A10107

AB0019096

AC-5545

AC1L1E7T

AC1Q768B

Acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-

Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-

AKOS003589059

AKOS021729457

Alerlisin

AN-10906

AN-15756

BBL009968

BCP08787

BCP28477

BDBM22890

Benaday

BPBio1_000469

BRD-A42571354-300-05-4

BRD-A42571354-300-07-0

BSPBio_000425

BSPBio_002302

C-5854

C07778

C21H25ClN2O3

CC0153

Cetiderm (TN)

Cetirizin

Cetirizina

Cetirizina [Spanish]

cetirizine

Cetirizine (INN)

Cetirizine [INN:BAN]

CETIRIZINE HYDROCHLORIDE

CetirizineHydrochloride

Cetirizinum

Cetirizinum [Latin]

Cetrizide

Cetrizine Dihcl

Cetrizine Hcl

Cetryn

CHEBI:3561

CHEMBL1000

CPD001453715

CS-0886

CTK7J5576

D07662

DB00341

DTXSID4022787

EN300-52521

FT-0603001

FT-0654660

GTPL1222

Hitrizin Film Tablet

HMS1539O07

HMS3259D06

HMS3370I19

HMS3393N10

HSDB 7739

HY-17042

I06-0454

J-005737

L000655

Levocetirizine HCl

LS-11409

MCULE-8668839822

MFCD00800721

MolPort-002-506-309

NC00696

NCGC00167781-01

NCGC00167781-02

NCGC00167781-03

NCGC00167781-04

NCGC00167781-07

Prestwick0_000503

Prestwick1_000503

Prestwick2_000503

Prestwick3_000503

RT-007014

SAM002548972

SAM002589989

SBI-0206838.P001

SC-17992

SC-18167

SC-19204

SC-19390

SCHEMBL4176

Setir

SPBio_002346

ST024755

STK711108

TimTec1_002075

U095

Virlix

Xarlin

Z1182332250

Ziptek

Zirtek

ZKLPARSLTMPFCP-UHFFFAOYSA-N

Zyrlex

Zyrtec Syrup

Zyrtec-D

US Patents and Regulatory Information for ZERVIATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eyevance	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes
Eyevance	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes					Y
Eyevance	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes			Y
Eyevance	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes					Y
Eyevance	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes
Eyevance	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes

International Patents for ZERVIATE

Country	Patent Number	Estimated Expiration
Japan	2012520882
Japan	2018141022
European Patent Office	2547340
Mexico	2011009802
Japan	2015007136
World Intellectual Property Organization (WIPO)	2010107689
Japan	6449202

Supplementary Protection Certificates for ZERVIATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103